Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06455956 | RECRUITING | Growth Hormone Deficiency

Use of miRNAs in Growth Hormone Deficiency (GHD)
Sponsor:

University of Parma

Brief Summary:

This study aims at improving knowledge about the diagnosis of growth hormone deficiency (GHD) and treatment with growth hormone (GH), with the goal of providing information on the presence of new biomarkers, such as miRNAs, for diagnostic and therapeutic purposes, with the goal of establishing a personalized GH treatment scheme, optimizing resources, reducing costs, and improving outcomes.

Condition or disease

Growth Hormone Deficiency

Detailed Description:

In 200 prepubertal and pubertal subjects with the suspicion of GHD, the levels of three specific circulating miRNas will be measured to establish whether they can be used for the diagnosis of GH deficiency. In subjects with isolated idiopathic GHD (IIGHD), short statured patients born SGA, Noonan and Turner syndromes, and SHOX deficiency, we will also assess the changes of the identified miRNAs before and after 3 months on GH therapy to verify an early growth prediction model for growth response at 12 months on treatment. Finally, we plan to identify any differences in these miRNAs at 3 months on treatment using daily GH versus weekly (long-acting) GH.

Study Type : OBSERVATIONAL
Estimated Enrollment : 400 participants
Official Title : New Potential Biomarkers for Diagnosis of Growth Hormone (GH) Deficiency and Early Assessment of Response to GH Treatment for Appropriate Personalization of Therapy
Actual Study Start Date : 2023-04-13
Estimated Primary Completion Date : 2025-03-31
Estimated Study Completion Date : 2026-03-01

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 2 Years to 15 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria for aim 1
  • * Children with short stature and suspicion of GHD
  • * Subjects with organic GH deficiency
  • Exclusion criteria for aim 1
    • -Subjects with underlying genetic conditions and chronic diseases
    • Inclusion Criteria for aim 2-3-5
      • * patients having confirmed GHD enrolled for aim 1
      • * patients with growth failure and born SGA (\>4 yr of age)
      • * patients with Noonan and Turner syndrome and growth failure
      • * patients with short stature homeobox-containing gene deficiency (SHOXD) and growth failure
      • Inclusion Criteria for aim 4
        • \- Isolated idiopathic prepubertal naive GHD subjects on long-acting versus daily GH therapy
Use of miRNAs in Growth Hormone Deficiency (GHD)

Location Details

NCT06455956

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

Italy, Emilia-Romagna

University of Parma

Parma, Emilia-Romagna, Italy, 43121